Media stories about Amicus Therapeutics (NASDAQ:FOLD) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Amicus Therapeutics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.8055642266147 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
A number of brokerages have recently commented on FOLD. Zacks Investment Research lowered shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Robert W. Baird set a $20.00 price target on shares of Amicus Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Cowen reiterated a “buy” rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 10th. Finally, Leerink Swann boosted their target price on shares of Amicus Therapeutics from $20.00 to $24.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Amicus Therapeutics currently has an average rating of “Buy” and a consensus target price of $19.06.
Shares of Amicus Therapeutics (FOLD) traded down $0.66 during midday trading on Friday, reaching $15.17. 11,011,319 shares of the company traded hands, compared to its average volume of 3,330,000. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. The company has a market capitalization of $2,420.00, a price-to-earnings ratio of -8.29 and a beta of 1.45. Amicus Therapeutics has a 12 month low of $5.87 and a 12 month high of $17.40.
In other Amicus Therapeutics news, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the transaction, the insider now owns 69,184 shares of the company’s stock, valued at $940,210.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO John F. Crowley sold 47,213 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $13.61, for a total transaction of $642,568.93. Following the transaction, the chief executive officer now directly owns 375,214 shares in the company, valued at approximately $5,106,662.54. The disclosure for this sale can be found here. Insiders have sold 250,390 shares of company stock valued at $3,620,581 over the last 90 days. 3.40% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics (FOLD) Receives Daily Coverage Optimism Score of 0.23” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/17/amicus-therapeutics-fold-receives-daily-media-impact-rating-of-0-23.html.
About Amicus Therapeutics
Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.